Pegsunercept
| Clinical data | |
|---|---|
| Routes of administration | subcutaneous injection |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C502H758N154O165S16 |
| Molar mass | 12103.46 g·mol−1 |
  (what is this?) (verify) | |
Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010[update], Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.
Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]
References
[edit]- ^ Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
- ^ Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
- ^ a b Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M (December 2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–10. PMID 16331754.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |